Waters Corporation (0LTI.L)
USD 370.56
(-0.36%)
USD 370.56
(-0.36%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2.95 Billion USD | -0.52% |
| 2022 | 2.97 Billion USD | 6.68% |
| 2021 | 2.78 Billion USD | 17.78% |
| 2020 | 2.36 Billion USD | -1.71% |
| 2019 | 2.4 Billion USD | -0.55% |
| 2018 | 2.41 Billion USD | 4.8% |
| 2017 | 2.3 Billion USD | 6.54% |
| 2016 | 2.16 Billion USD | 6.12% |
| 2015 | 2.04 Billion USD | 2.66% |
| 2014 | 1.98 Billion USD | 4.47% |
| 2013 | 1.9 Billion USD | 3.29% |
| 2012 | 1.84 Billion USD | -0.41% |
| 2011 | 1.85 Billion USD | 12.65% |
| 2010 | 1.64 Billion USD | 9.65% |
| 2009 | 1.49 Billion USD | -4.85% |
| 2008 | 1.57 Billion USD | 6.93% |
| 2007 | 1.47 Billion USD | 15.06% |
| 2006 | 1.28 Billion USD | 10.53% |
| 2005 | 1.15 Billion USD | 4.86% |
| 2004 | 1.1 Billion USD | 15.27% |
| 2003 | 958.2 Million USD | 7.67% |
| 2002 | 889.96 Million USD | 3.58% |
| 2001 | 859.2 Million USD | 8.07% |
| 2000 | 795.07 Million USD | 12.87% |
| 1999 | 704.4 Million USD | 13.83% |
| 1998 | 618.8 Million USD | 32.93% |
| 1997 | 465.5 Million USD | 19.02% |
| 1996 | 391.1 Million USD | 17.45% |
| 1995 | 333 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 636.83 Million USD | -22.29% |
| 2024 Q3 | 740.3 Million USD | 4.48% |
| 2024 Q2 | 708.52 Million USD | 11.26% |
| 2023 Q2 | 740.57 Million USD | 8.16% |
| 2023 Q1 | 684.67 Million USD | -20.25% |
| 2023 Q4 | 819.47 Million USD | 15.14% |
| 2023 FY | 2.95 Billion USD | -0.52% |
| 2023 Q3 | 711.69 Million USD | -3.9% |
| 2022 Q3 | 708.55 Million USD | -0.81% |
| 2022 Q4 | 858.51 Million USD | 21.16% |
| 2022 FY | 2.97 Billion USD | 6.68% |
| 2022 Q1 | 690.57 Million USD | -17.44% |
| 2022 Q2 | 714.31 Million USD | 3.44% |
| 2021 Q4 | 836.44 Million USD | 26.88% |
| 2021 FY | 2.78 Billion USD | 17.78% |
| 2021 Q2 | 681.64 Million USD | 12.01% |
| 2021 Q3 | 659.23 Million USD | -3.29% |
| 2021 Q1 | 608.54 Million USD | -22.64% |
| 2020 Q3 | 593.78 Million USD | 14.19% |
| 2020 Q2 | 519.98 Million USD | 11.84% |
| 2020 FY | 2.36 Billion USD | -1.71% |
| 2020 Q1 | 464.93 Million USD | -35.09% |
| 2020 Q4 | 786.65 Million USD | 32.48% |
| 2019 Q3 | 577.27 Million USD | -3.65% |
| 2019 FY | 2.4 Billion USD | -0.55% |
| 2019 Q1 | 513.86 Million USD | -28.13% |
| 2019 Q2 | 599.16 Million USD | 16.6% |
| 2019 Q4 | 716.29 Million USD | 24.08% |
| 2018 Q4 | 715.01 Million USD | 23.7% |
| 2018 FY | 2.41 Billion USD | 4.8% |
| 2018 Q2 | 596.21 Million USD | 12.35% |
| 2018 Q1 | 530.67 Million USD | -22.79% |
| 2018 Q3 | 578.02 Million USD | -3.05% |
| 2017 Q3 | 565.58 Million USD | 1.31% |
| 2017 FY | 2.3 Billion USD | 6.54% |
| 2017 Q4 | 687.27 Million USD | 21.52% |
| 2017 Q1 | 497.96 Million USD | -20.8% |
| 2017 Q2 | 558.25 Million USD | 12.11% |
| 2016 Q4 | 628.78 Million USD | 19.35% |
| 2016 Q2 | 536.56 Million USD | 12.9% |
| 2016 Q1 | 475.24 Million USD | -18.98% |
| 2016 FY | 2.16 Billion USD | 6.12% |
| 2016 Q3 | 526.83 Million USD | -1.81% |
| 2015 Q1 | 460.4 Million USD | -21.15% |
| 2015 Q3 | 500.57 Million USD | 1.18% |
| 2015 Q4 | 586.61 Million USD | 17.19% |
| 2015 FY | 2.04 Billion USD | 2.66% |
| 2015 Q2 | 494.74 Million USD | 7.46% |
| 2014 Q1 | 430.5 Million USD | -23.86% |
| 2014 Q2 | 481.8 Million USD | 11.91% |
| 2014 Q3 | 493.16 Million USD | 2.36% |
| 2014 Q4 | 583.87 Million USD | 18.39% |
| 2014 FY | 1.98 Billion USD | 4.47% |
| 2013 FY | 1.9 Billion USD | 3.29% |
| 2013 Q4 | 565.44 Million USD | 23.64% |
| 2013 Q1 | 430.33 Million USD | -17.52% |
| 2013 Q3 | 457.31 Million USD | 1.37% |
| 2013 Q2 | 451.11 Million USD | 4.83% |
| 2012 Q1 | 420.45 Million USD | -19.36% |
| 2012 Q2 | 451.46 Million USD | 7.37% |
| 2012 Q3 | 449.95 Million USD | -0.34% |
| 2012 Q4 | 521.76 Million USD | 15.96% |
| 2012 FY | 1.84 Billion USD | -0.41% |
| 2011 Q1 | 427.6 Million USD | -11.58% |
| 2011 FY | 1.85 Billion USD | 12.65% |
| 2011 Q3 | 454.53 Million USD | 1.54% |
| 2011 Q4 | 521.42 Million USD | 14.72% |
| 2011 Q2 | 447.62 Million USD | 4.68% |
| 2010 Q2 | 391.05 Million USD | 6.35% |
| 2010 FY | 1.64 Billion USD | 9.65% |
| 2010 Q4 | 483.57 Million USD | 20.58% |
| 2010 Q3 | 401.03 Million USD | 2.55% |
| 2010 Q1 | 367.7 Million USD | -14.26% |
| 2009 Q4 | 428.84 Million USD | 14.68% |
| 2009 FY | 1.49 Billion USD | -4.85% |
| 2009 Q2 | 362.83 Million USD | 8.94% |
| 2009 Q3 | 373.96 Million USD | 3.07% |
| 2009 Q1 | 333.05 Million USD | -20.39% |
| 2008 FY | 1.57 Billion USD | 6.93% |
| 2008 Q4 | 418.33 Million USD | 8.29% |
| 2008 Q3 | 386.31 Million USD | -3.12% |
| 2008 Q2 | 398.77 Million USD | 7.28% |
| 2008 Q1 | 371.71 Million USD | -14.94% |
| 2007 Q1 | 330.77 Million USD | -14.51% |
| 2007 Q3 | 352.63 Million USD | 0.0% |
| 2007 Q2 | 352.63 Million USD | 6.61% |
| 2007 Q4 | 437 Million USD | 23.92% |
| 2007 FY | 1.47 Billion USD | 15.06% |
| 2006 FY | 1.28 Billion USD | 10.53% |
| 2006 Q2 | 301.89 Million USD | 4.02% |
| 2006 Q1 | 290.21 Million USD | -12.66% |
| 2006 Q3 | 301.18 Million USD | -0.24% |
| 2006 Q4 | 386.93 Million USD | 28.47% |
| 2005 FY | 1.15 Billion USD | 4.86% |
| 2005 Q2 | 284.63 Million USD | 6.08% |
| 2005 Q3 | 273.03 Million USD | -4.08% |
| 2005 Q4 | 332.27 Million USD | 21.7% |
| 2005 Q1 | 268.3 Million USD | -17.23% |
| 2004 FY | 1.1 Billion USD | 15.27% |
| 2004 Q1 | 255.08 Million USD | -7.27% |
| 2004 Q2 | 260.48 Million USD | 2.12% |
| 2004 Q3 | 264.8 Million USD | 1.66% |
| 2004 Q4 | 324.15 Million USD | 22.41% |
| 2003 Q4 | 275.07 Million USD | 19.4% |
| 2003 FY | 958.2 Million USD | 7.67% |
| 2003 Q3 | 230.38 Million USD | -0.59% |
| 2003 Q1 | 220.99 Million USD | -13.8% |
| 2003 Q2 | 231.75 Million USD | 4.87% |
| 2002 Q4 | 256.38 Million USD | 18.67% |
| 2002 Q3 | 216.04 Million USD | -0.53% |
| 2002 Q2 | 217.19 Million USD | 8.41% |
| 2002 Q1 | 200.34 Million USD | -19.44% |
| 2002 FY | 889.96 Million USD | 3.58% |
| 2001 Q1 | 202.51 Million USD | -10.02% |
| 2001 Q2 | 206.8 Million USD | 2.12% |
| 2001 Q4 | 248.67 Million USD | 22.69% |
| 2001 Q3 | 202.69 Million USD | -1.99% |
| 2001 FY | 859.2 Million USD | 8.07% |
| 2000 Q4 | 225.08 Million USD | 15.98% |
| 2000 Q1 | 180.64 Million USD | -9.99% |
| 2000 Q2 | 195.27 Million USD | 8.1% |
| 2000 Q3 | 194.07 Million USD | -0.62% |
| 2000 FY | 795.07 Million USD | 12.87% |
| 1999 Q1 | 160.4 Million USD | -10.39% |
| 1999 FY | 704.4 Million USD | 13.83% |
| 1999 Q4 | 200.7 Million USD | 17.3% |
| 1999 Q3 | 171.1 Million USD | -0.7% |
| 1999 Q2 | 172.3 Million USD | 7.42% |
| 1998 FY | 618.8 Million USD | 32.93% |
| 1998 Q4 | 179 Million USD | 17.92% |
| 1998 Q3 | 151.8 Million USD | 1.67% |
| 1998 Q2 | 149.3 Million USD | 7.64% |
| 1998 Q1 | 138.7 Million USD | -8.63% |
| 1997 Q3 | 105 Million USD | -1.13% |
| 1997 Q4 | 151.8 Million USD | 44.57% |
| 1997 Q1 | 102.4 Million USD | -8.08% |
| 1997 FY | 465.5 Million USD | 19.02% |
| 1997 Q2 | 106.2 Million USD | 3.71% |
| 1996 FY | 391.1 Million USD | 17.45% |
| 1996 Q3 | 98.4 Million USD | 2.5% |
| 1996 Q2 | 96 Million USD | 12.54% |
| 1996 Q1 | 85.3 Million USD | -5.75% |
| 1996 Q4 | 111.4 Million USD | 13.21% |
| 1995 Q3 | 80.6 Million USD | -4.39% |
| 1995 Q1 | 77.6 Million USD | 0.0% |
| 1995 FY | 333 Million USD | 0.0% |
| 1995 Q4 | 90.5 Million USD | 12.28% |
| 1995 Q2 | 84.3 Million USD | 8.63% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Editas Medicine, Inc. | 78.12 Million USD | -3684.309% |
| Dynavax Technologies Corporation | 232.28 Million USD | -1172.759% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | -386.636% |
| Perrigo Company plc | 4.65 Billion USD | 36.498% |
| Illumina, Inc. | 4.5 Billion USD | 34.36% |
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 93.102% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -248547.267% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 97.998% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 80.27% |
| Heron Therapeutics, Inc. | 127.04 Million USD | -2227.08% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 77.462% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| Biogen Inc. | 9.83 Billion USD | 69.942% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | -1577.57% |
| Evolus, Inc. | 202.08 Million USD | -1362.957% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -13999.657% |
| bluebird bio, Inc. | 29.49 Million USD | -9922.768% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -2441.317% |
| FibroGen, Inc. | 147.75 Million USD | -1900.931% |
| Agilent Technologies, Inc. | 6.83 Billion USD | 56.733% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Homology Medicines, Inc. | -6.65 Million USD | 44550.699% |
| Geron Corporation | 237 Thousand USD | -1247332.911% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | -61.704% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | -640.296% |
| Myriad Genetics, Inc. | 678.4 Million USD | -335.792% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | -8050.01% |
| Zoetis Inc. | 8.54 Billion USD | 65.398% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -84369.029% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | 21.959% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | -22.205% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 70.044% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | -275.348% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -34385.198% |
| Verastem, Inc. | - USD | -Infinity% |
| Nektar Therapeutics | 90.12 Million USD | -3180.46% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | -992.541% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -9360.834% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | -137.781% |
| OPKO Health, Inc. | 863.49 Million USD | -242.378% |
| Exelixis, Inc. | 1.83 Billion USD | -61.534% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | -56.665% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | -512.887% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 15.84 Million USD | -18560.708% |
| Imunon, Inc. | - USD | -Infinity% |
| Blueprint Medicines Corporation | 249.38 Million USD | -1085.506% |
| Insmed Incorporated | 305.2 Million USD | -868.656% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | -256.516% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -10921.944% |
| TG Therapeutics, Inc. | 233.66 Million USD | -1165.253% |
| Incyte Corporation | 3.69 Billion USD | 20.003% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -181.751% |